Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development expenses	$ 2,343,154	$ 1,081,705	$ 6,539,948	$ 1,988,450
General and administrative expenses	1,653,072	1,151,542	4,341,880	2,798,766
Operating Costs and Expenses, Total	3,996,226	2,233,247	10,881,828	4,787,216
Loss from operations	(3,996,226)	(2,233,247)	(10,881,828)	(4,787,216)
Other income (expense):
Interest expense	(1,716)	(451,306)	(1,820)	(827,539)
Interest income	348	708	1,249	1,501
Australian research and development incentives	65,111		230,188
Change in fair value of embedded features		(96,000)		(203,000)
Change in fair value of warrant liability		(100,780)		(1,546,280)
Loss on extinguishment of convertible notes and convertible notes, related parties		(2,322,943)		(2,322,943)
Other income (expense), net	63,743	(2,970,321)	229,617	(4,898,261)
Net loss	(3,932,483)	(5,203,568)	(10,652,211)	(9,685,477)
Net loss attributable to noncontrolling interests		(7,130)		(74,331)
Deemed dividend on warrant modification			(450,578)
Deemed dividend for ratchet shares issued at IPO	(1,099,360)		(1,099,360)
Net loss attributable to MAIA Biotechnology, Inc. shareholders	$ (5,031,843)	$ (5,196,438)	$ (12,202,149)	$ (9,611,146)
Net loss per share
Net loss per share basic	$ (0.49)	$ (1.02)	$ (1.40)	$ (2.06)
Net loss per share diluted	$ (0.49)	$ (1.02)	$ (1.40)	$ (2.06)
Weighted average common shares outstanding basic	10,165,622	5,119,121	8,713,570	4,668,635
Weighted average common shares outstanding diluted	10,165,622	5,119,121	8,713,570	4,668,635